Eli Lilly and Co.

To keep sales force busy, Lilly takes on new drug

December 24, 2009
J.K. Wall
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel to push.
More

Lilly pays $90 million for autoimmune drug

December 21, 2009
 IBJ Staff
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune diseases.
More

Senate rejects drug-importation proposal

December 16, 2009
 IBJ Staff and Associated Press
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers such as Indianapolis-based Eli Lilly and Co. a victory.
More

Lilly wins approval for long-acting Zyprexa

December 14, 2009
J.K. Wall
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
More

Eli Lilly's shares slip after it forecasts mixed profits in coming years

December 10, 2009
 IBJ Staff and Associated Press
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results could fall precipitously.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Ariad asks court to restore patent-suit win against Lilly

December 8, 2009
 IBJ Staff
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent claim.
More

Builder looks to cold storage for steady work in a weak economyRestricted Content

December 5, 2009
Brock Benefiel
Cold storage might become a hot business for a building contractor.
More

Part of Mississippi's Zyprexa case against Lilly dismissed

December 2, 2009
 IBJ Staff
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges improper marketing of antipsychotic drug Zyprexa for unapproved uses.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly's Cymbalta wins new approval for anxiety disorder

November 30, 2009
J.K. Wall
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Lilly to pay Utah $24 million to settle Zyprexa suit

November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic drug Zyprexa.
More

Lilly, WellPoint CEOs pin hopes on Senate

November 11, 2009
J.K. Wall
Drugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
More

Lilly reducing sales force by 191 as part of larger restructuring

November 2, 2009
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring announced in September that ultimately will result in 5,500 job cuts by the end of 2011.
More

TechPoint to focus on IT firms specializing in medical, life sciences sectorsRestricted Content

October 31, 2009
Chris O'Malley
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
More

Lilly opens new biotech center in San Diego

October 29, 2009
J.K. Wall
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
More

Lilly to move 1,000 from Faris campus

October 26, 2009
J.K. Wall
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate center by mid-2010.
More

Lilly needs to sell more Effient before Zyprexa loses patent protectionRestricted Content

October 24, 2009
J.K. Wall
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for the quarter.
More

Lilly settles Zyprexa case with S. Carolina for $45M

October 23, 2009
 IBJ Staff and Associated Press
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker Eli Lilly and Co. over the company's marketing of an anti-psychotic drug.
More

Eli Lilly CEO banking on new drug pipeline

October 22, 2009
Associated Press
CEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year career at the company. He's betting there will be a fourth.
More

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Uncertainty over drug pipeline sends Lilly shares down

October 21, 2009
J.K. Wall
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
More

Lilly reports $942 million profit in third quarter

October 21, 2009
J.K. Wall
Excluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008, to $5.56 billion.
More

Medco plans to compare Plavix, Effient in study

October 20, 2009
 IBJ Staff and Associated Press
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
More
Page  << 21 22 23 24 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT